[Report] Merck & Co Inc. PharmaVitae Profile Market Research, Trends, Analysis TOC

CHAPTER 1 EXECUTIVE SUMMARY
- Key findings
- Historical and forecast ethical sales performance
- Therapeutic strategy
- Launch and expiry outlook
- Externalization, geographic and molecule type strategies
  - Externalization strategy
  - Geographic strategy
  - Molecule type strategy
- SWOT analysis
  - Strengths
  - Weaknesses
  - Opportunities
  - Threats
CHAPTER 2 CORPORATE HISTORY
- Key findings
- Background
- Key corporate developments
  - Merck & Co. global restructuring plan: December 2005 - highlights
- M&A history
  - Divestments
  - Acquisitions
    - GlycoFi
    - Abmaxis
    - Sirna Therapeutics
    - NovaCardia
CHAPTER 3 HISTORICAL PERFORMANCE
- Key findings
- Introduction
- Revenue and growth rate analysis, 2001-06
  - Revenue and growth rate vs. peer set
- Product analysis, 2001-06
  - Growth drivers
    - Singulair
    - Zetia/Vytorin
    - Fosamax
  - Growth resistors
    - Zocor
    - Vioxx
- Operating revenue and cost analysis, 2001-06
  - Operating revenue/cost analysis
CHAPTER 4 FORECAST PERFORMANCE
- Key findings
- Introduction
- Revenue and growth rate, 2006-12
- Product analysis, 2006-12
  - Growth drivers
    - Januvia
    - Zetia/Vytorin
    - Gardasil
    - Others
  - Growth resistors
    - Zocor
    - Fosamax
    - Cozaar/Hyzaar
- Therapy area analysis, 2006-12
  - Endocrine, metabolic and genetic disorders
  - Infectious diseases
  - Oncology
  - Cardiovascular & hematology
  - Musculoskeletal
  - Therapy area focus
- Launches and expiries analysis, 2006-12
  - Launch portfolio
  - Core portfolio
  - Expiry portfolio
  - Launch/core/expiry configuration
- Externalization analysis, 2006-12
- Geographic analysis, 2006-12
- Molecule type analysis, 2006-12
CHAPTER 5 KEY PRODUCTS AND COMPETITORS
- Key findings
- Overview
- Cardiovascular
  - Zetia/Vytorin
    - Overview
    - Sales forecast
    - Newsflow
  - MK-0524B
    - Overview
    - Sales forecast
    - Newsflow
  - Cozaar/Hyzaar
    - Overview
    - Sales forecast
    - Newsflow
  - Zocor
    - Overview
    - Sales forecast
    - Newsflow
- Respiratory
  - Singulair
    - Overview
    - Sales forecast
    - Newsflow
- Endocrine, metabolic & genetic disorders
  - Januvia
    - Overview
    - Sales forecast
    - Newsflow
- Oncology
  - Gardasil
    - Overview
    - Sales forecast
    - Newsflow
- Musculoskeletal
  - Fosamax
    - Overview
    - Sales forecast
    - Newsflow
- R&D pipeline
CHAPTER 6 APPENDIX
- IMS vs. company-reported data reconciliation
- Abbreviations
- List of Tables
  - Table 1: Peer set overview
  - Table 2: Operating revenue/cost analysis ($m), 2001-06
  - Table 3: Operating cost ratio analysis (% of total revenues), 2001-06
  - Table 4: Product portfolio overview, sales ($m), 2006-12
  - Table 5: Therapy area overview, sales ($m), 2006-12
  - Table 6: Launch portfolio overview, sales ($m), 2006-12
  - Table 7: Core portfolio overview, sales ($m), 2006-12
  - Table 8: Expiry portfolio overview, sales ($m), 2006-12
  - Table 9: Externally developed portfolio ($m), 2006-12
  - Table 10: Molecule type overview, sales ($m), 2006-12
  - Table 11: Key products overview
  - Table 12: Zetia/Vytorin: overview
  - Table 13: Zetia/Vytorin: sales forecast ($m), 2006-12
  - Table 14: Zetia/Vytorin: news flow
  - Table 15: Antidyslipidemic market overview, 7MM sales ($m), 2006
  - Table 16: MK-0524B: overview
  - Table 17: MK-0524B: sales forecast ($m), 2006-12
  - Table 18: MK-0524B: news flow
  - Table 19: Cozaar/Hyzaar: overview
  - Table 20: Cozaar: sales forecast ($m), 2006-12
  - Table 21: Hyzaar: sales forecast ($m), 2006-12
  - Table 22: Cozaar/Hyzaar: news flow
  - Table 23: Zocor: overview
  - Table 24: Zocor: sales forecast ($m), 2006-12
  - Table 25: Zocor: news flow
  - Table 26: Singulair: overview
  - Table 27: Singulair: sales forecast ($m), 2006-12
  - Table 28: Singulair: news flow
  - Table 29: Januvia: overview
  - Table 30: Januvia: sales forecast ($m), 2006-12
  - Table 31: Januvia: news flow
  - Table 32: Gardasil: overview
  - Table 33: Gardasil: sales forecast ($m), 2006-12
  - Table 34: Gardasil: news flow
  - Table 35: Fosamax: overview
  - Table 36: Fosamax: sales forecast ($m), 2006-12
  - Table 37: Fosamax: news flow
  - Table 38: Merck & Co.' s R&D pipeline (Phase I-registration)
- List of Figures
  - Figure 1: Historical and forecast ethical sales performance (% CAGR), Merck & Co. and Big Pharma peer set
  - Figure 2: Therapeutic focus vs. Big Pharma peer set (%), 2006
  - Figure 3: Launch, core and expiry, absolute sales growth, 2006-12 (sales as % of 2006 sales), Merck & Co.
  - Figure 4: Launch, core and expiry, absolute sales growth, 2006-12 (sales as % of 2006 sales), peer set
  - Figure 5: Molecule type, externalization and geographic market dependency (%) vs. peer set, 2006
  - Figure 6: Molecule type, externalization and geographic market dependency (%) vs. peer set, 2012
  - Figure 7: SWOT analysis of Merck & Co.
  - Figure 8: Revenue & growth rate (ethical sales) ($m), 2001-06
  - Figure 9: Ethical revenue ($m) and growth rate (%) vs. peer set, 2001-06
  - Figure 10: Growth drivers/resistor products of historical revenue performance ($m), 2001-06
  - Figure 11: Operating revenue/cost analysis ($m), 2001-06
  - Figure 12: Operating cost ratio analysis (% of total revenues), 2001-06
  - Figure 13: Ethical revenue ($m) and growth rate (%), 2006-12
  - Figure 14: Top five products by sales ($m), 2006
  - Figure 15: Top five products by sales ($m), 2012
  - Figure 16: Growth drivers and resistors by product, 2006-12
  - Figure 17: Key strategic products, sales ($m), 2006-12
  - Figure 18: Ethical sales by therapy area ($m), 2006-12
  - Figure 19: Growth drivers and resistors by therapy area ($m), 2006-12
  - Figure 20: Ethical sales by therapy area (%), 2006-12
  - Figure 21: Therapy area focus compared with peer set (% total ethical sales), 2006
  - Figure 22: Therapy area focus compared with peer set (% total ethical sales), 2012
  - Figure 23: Launch schedule, sales ($m), 2006-12
  - Figure 24: Core products sales growth ($m), 2006-12
  - Figure 25: Expiry schedule, sales ($m), 2006-12
  - Figure 26: Launch, core and expiry, sales ($m), 2006-12
  - Figure 27: Launch, core and expiry, absolute sales growth, 2006-12 (sales as % of 2006 sales), Merck & Co.
  - Figure 28: Launch, core and expiry, absolute sales growth, 2006-12 (sales as % of 2006 sales), peer set
  - Figure 29: Externalization dependency, sales ($m), 2006-12
  - Figure 30: Growth drivers and resistors, externally vs. internally discovered products, sales ($m), 2006-12
  - Figure 31: Externalization dependency vs. peer set, % total sales, 2006
  - Figure 32: Externalization dependency vs. peer set, % total sales, 2012
  - Figure 33: Geographical sales breakdown ($m), 2006-12
  - Figure 34: Growth drivers and resistors by geography, sales ($m), 2006-12
  - Figure 35: US dependency vs. peer set, % total sales, 2006
  - Figure 36: US dependency vs. peer set, % total sales, 2012
  - Figure 37: Molecule type sales breakdown ($m), 2006-12
  - Figure 38: Growth drivers and resistors by molecule type, sales ($m), 2006-12
  - Figure 39: Biologics dependency vs. peer set, % total sales, 2006
  - Figure 40: Biologics dependency vs. peer set, % total sales, 2012
  - Figure 41: Top five antidyslipidemic drug quarterly sales ($m), 7MM, 2006
  - Figure 42: IMS vs. company-reported ethical sales discrepancy ($m), 2006
  - Figure 43: IMS vs. company-reported ethical sales forecast growth rates (%), 2006-12

Merck & Co., Inc.: PharmaVitae Profile

Table of Contents